ARCHIVES

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCAB Sets Bypass Budget Figures at $1.074 Billion

May 28, 1982

FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.

September 16, 2005

Hopkins Challenges Litton For Research Contract At FCRF

April 16, 1982

In Brief: NCAB To Hear NCI Staff Plans For Implementing Recommendation On Nutrition & Cancer Task Force

October 1, 1982

NCI “Leadership Vacuum” Deepened?

December 22, 1994

DCT Board Okays $3 Million In New Programs, $8 Million In Recompetitions

October 24, 1980